Extended Data Fig. 1: Neutralizing antibodies persist for up to 10 months post onset of symptoms.
a) ID50 of neutralization for all wave 1 sera included in Fig. 1g. b) Correlation between ID50 (measured against spike pseudotyped virus) and either optimal density of IgG binding to S, RBD or N. (r2 = 0.6942), RBD (r2 = 0.6250) and N protein (r2 = 0.3861) (Spearman’s correlation, two-tailed, r; a linear regression was used to calculate the goodness of fit, r2). c) Percentage of individuals in each time window with undetectable (ID50 < 25), low (ID50 25 – 200), medium (ID50 201 – 500), high (ID50 501 – 2,000) or potent (ID50 2,000 + ) neutralizing antibody titres. The peak neutralization time point (n = 110) includes hospitalized patients and healthcare workers reported in Seow et al8, as well as 14 additional donors reported in this study. The time point from the longitudinal samples with the peak ID50 was used in ‘peak’. The first four bars show ID50 values measured against wild-type Spike pseudotyped virus (PV). The final bar show ID50 values measured against infectious SARS-CoV-2 virus (IV) for sera collected between 257-305 days POS. d) Correlation between ID50 values measured using wild-type infectious virus and pseudotyped virus for selected sera (n = 36) (Spearman correlation, two-tailed, r). A linear regression was used to calculate the goodness of fit (r2). The dotted lines represent the lowest serum dilution used in each assay. Sera which did not reach 50% neutralization at 1:25 dilution are given a value of 10 and is not included in the correlation.
